Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Solid Biosciences

How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback

Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.

Investors Business Daily

Stocks That Hit 52-Week Lows On Friday

Stocks That Hit 52-Week Lows On Friday

During Friday, 125 stocks hit new 52-week lows.

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

What 4 Analyst Ratings Have To Say About Solid Biosciences

Over the past 3 months, 4 analysts have published their opinion on Solid Biosciences (NASDAQ:SLDB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Looking Into Solid Biosciences's Return On Capital Employed

Solid Biosciences (NASDAQ:SLDB) brought in sales totaling $1.93 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 36.1%, resulting in a loss of $25.33 million.

Duchenne Player Solid Biosciences Realigns Pipeline Strategy, Cuts Staff By 35%

Solid Biosciences Inc (NASDAQ: SLDB) is shaving down its pipeline, updating its operations strategy to prioritize the advancement of AAV-mediated gene transfer therapies, SGT-001 and SGT-003.

Recap: Solid Biosciences Q1 Earnings

Solid Biosciences (NASDAQ:SLDB) reported its Q1 earnings results on Wednesday, April 27, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

inkl

Read news from The Economist, FT, and more,
with one subscription

Earnings Outlook For Solid Biosciences

Earnings Outlook For Solid Biosciences

Solid Biosciences (NASDAQ:SLDB) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Solid Biosciences will report an earnings per share (EPS) of $-0.18.

Solid Biosciences's Return On Capital Employed Insights

Solid Biosciences's Return On Capital Employed Insights

Benzinga Pro data, Solid Biosciences (NASDAQ:SLDB) reported Q4 sales of $3.15 million. Earnings fell to a loss of $18.61 million, resulting in a 3.49% decrease from last quarter.

Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial

Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial

Solid Biosciences Inc (NASDAQ:SLDB) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose (2E14 vg/kg) cohort as part of IGNITE DMD. Results suggest durable benefit 24-months post-administration of SGT-001 compared to natural history, consistent with results reported at the 12-month and 18-month…

Recap: Solid Biosciences Q4 Earnings

Recap: Solid Biosciences Q4 Earnings

Solid Biosciences (NASDAQ:SLDB) reported its Q4 earnings results on Monday, March 14, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Organisations

First Republic Bank

Lloyds Banking Group

Regeneron Pharmaceuticals

Petrobras Brasileiro

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play